Literature DB >> 19243557

HLA-Cw4 expression on porcine endothelial cells reduces cytotoxicity and adhesion mediated by CD158a+ human NK cells.

Pietro Forte1, Bettina C Baumann, Mårten K J Schneider, Jörg D Seebach.   

Abstract

BACKGROUND: Human natural killer (NK) cell-mediated cytotoxicity represents a hurdle in pig-to-human xenotransplantation. It was previously reported that the expression of human major histocompatibility complex class I molecules, including HLA-B27, -Cw3, -E, and -G, partially protects porcine endothelial cells (pEC) from human NK-mediated cytotoxicity and that HLA-G inhibits NK adhesion to pEC. Here, we tested if HLA-Cw4 expression on pEC alone, or concurrently with HLA-Cw3, prevents human NK adhesion and cytotoxicity against pEC via recognition of the killer-cell immunoglobulin-like receptors (KIR) CD158a (KIR2DL1) and CD158b (KIR2DL2/3), respectively.
METHODS: Two pEC lines (2A2 and PEDSV.15) were transfected with HLA-Cw3 and HLA-Cw4. HLA and KIR expression on porcine and human cells were analyzed by flow cytometry. The effect of HLA expression on pEC on human NK-mediated cytotoxicity and adhesion was tested by (51)Cr-release and dynamic adhesion assays, respectively.
RESULTS: HLA-Cw4 expression on pEC reduced cytotoxicity mediated by CD158a(+) polyclonal human NK cells by an average of 58%, and by CD158a(bright) NK cell clones by 68%, but not by NK cells expressing low levels of CD158. Co-expression of HLA-Cw3 and HLA-Cw4 on pEC did not mediate further protection against NK cytotoxicity. The expression of HLA-Cw4 reduced the adhesion of human NK cells on pEC by a mean of 53%.
CONCLUSIONS: While transgenic expression of HLA-Cw4 on pEC reduces NK cell adhesion and cytotoxicity, co-expression with HLA-Cw3 is not sufficient to completely overcome human NK-mediated cytotoxicity in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19243557     DOI: 10.1111/j.1399-3089.2009.00510.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  19 in total

1.  Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).

Authors:  Shuzhen Liang; Mao Lin; Lizhi Niu; Kecheng Xu; Xiaohua Wang; Yingqing Liang; Mingjie Zhang; Duanming Du; Jibing Chen
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

2.  Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer.

Authors:  Mao Lin; Shu-Zhen Liang; Xiao-Hua Wang; Ying-Qing Liang; Ming-Jie Zhang; Li-Zhi Niu; Ji-Bing Chen; Hai-Bo Li; Ke-Cheng Xu
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

3.  Granzyme B is recovered by natural killer cells via clathrin-dependent endocytosis.

Authors:  Pan Li; Guoying Zheng; Yan Yang; Chunguang Zhang; Ping Xiong; Yong Xu; Min Fang; Zheng Tan; Fang Zheng; Feili Gong
Journal:  Cell Mol Life Sci       Date:  2010-05-07       Impact factor: 9.261

Review 4.  Innate cellular immunity and xenotransplantation.

Authors:  Hui Wang; Yong-Guang Yang
Journal:  Curr Opin Organ Transplant       Date:  2012-04       Impact factor: 2.640

5.  Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.

Authors:  Mao Lin; Shuzhen Liang; Xiaohua Wang; Yinqing Liang; Mingjie Zhang; Jibing Chen; Lizhi Niu; Kecheng Xu
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-04       Impact factor: 4.553

Review 6.  IXA Honorary Member Lecture, 2017: The long and winding road to tolerance.

Authors:  Megan Sykes
Journal:  Xenotransplantation       Date:  2018-05       Impact factor: 3.907

7.  Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor.

Authors:  Tae-Jin Kim; Nayoung Kim; Eun-Ok Kim; Jong-Rip Choi; Jeffrey A Bluestone; Kyung-Mi Lee
Journal:  Immunology       Date:  2010-04-06       Impact factor: 7.397

8.  Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study.

Authors:  Zilin Qin; Jibing Chen; Jianying Zeng; Lizhi Niu; Silun Xie; Xiaohua Wang; Yingqing Liang; Zhenyi Wu; Mingjie Zhang
Journal:  Cancer Biol Ther       Date:  2017-03-29       Impact factor: 4.742

Review 9.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

Review 10.  Current status of xenotransplantation and prospects for clinical application.

Authors:  Richard N Pierson; Anthony Dorling; David Ayares; Michael A Rees; Jörg D Seebach; Jay A Fishman; Bernhard J Hering; David K C Cooper
Journal:  Xenotransplantation       Date:  2009 Sep-Oct       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.